Equities research analysts at RBC Capital boosted their target price on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from $35.00 to $40.00 in a report released on Friday, Marketbeat reports. The firm presently has a “sector perform” rating on the stock. RBC Capital’s price target would suggest a potential downside of 2.58% from the stock’s previous close.

Fresenius Medical Care AG & Co. (NYSE:FMS) opened at 41.04 on Friday. The firm has a 50-day moving average price of $42.60 and a 200 day moving average price of $41.17. The firm has a market capitalization of $24.94 billion and a price-to-earnings ratio of 23.74. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.03. The firm earned $4.20 billion during the quarter, compared to the consensus estimate of $4.13 billion. The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.42 earnings per share. On average, equities analysts forecast that Fresenius Medical Care AG & Co. will post $1.76 EPS for the current year.

Separately, Commerzbank AG downgraded shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $37.78.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...